Conflict of Interest Disclosures: Dr Locatelli reported speakers' bureau and/or advisory board membership for Amgen, Novartis, Bellicum Pharmaceuticals, Miltenyi, Jazz Pharmaceuticals, Takeda, Neovi, and Medac. Dr Zugmaier reported receiving personal fees from Amgen, issue of patents (20190300609, 20130323247, and 20110262440), and having patents pending (10696744, 10662243, 20190142846, 20190142846, 20170327581, 10130638, 9688760, 20170122947, 9486475, 20160208001, 9192665, 20150071928, 8840888, 20140228316, 20140227272, 20130287778, and 20130287774). Dr von Stackelberg reported advisory board membership for Amgen, Novartis, MorphoSys, Jazz Pharmaceuticals, and Shire.


CORRECTION

Incorrect Figure: In the Original Investigation titled “Radiofrequency Ablation vs Antiarrhythmic Drugs as First-Line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2): A Review,” published in the February 19, 2014, issue of JAMA, the graphs in Figure 2 were reversed. This article was corrected online.


Guidelines for Letters

Letters discussing a recent JAMA article should be submitted within 4 weeks of the article's publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the JAMA article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jamanetwork.com/journals/jama/pages/instructions-for-authors. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment are required before publication. Letters should be submitted via the JAMA online submission and review system at https://manuscripts.jama.com. For technical assistance, please contact jama-letters@jamanetwork.org.

Section Editor: Jody W. Zylke, MD, Deputy Editor.